Dental Implant Deal Activity Heating Up
Posted in Dental Implant News
« Adverse Reaction to Dental Implant Materials | FDA Comments on Human Tissue Risks »
Subscribe to this PostHealthpoint Capital is making waves again in the dental implant industry. Fresh on the heels of their recent acquisition of BioHorizons, the private equity firm announced late last week that they were going to acquire publicly-traded BioLok for approximately $35 million.
"We have been successfully building our presence in the dental market,
which is one of the fastest growing sectors in the medical technology
industry," stated Mortimer Berkowitz III, President and Managing
Director of HealthpointCapital. "The addition of BioLok represents a
key point of our technology-driven strategy in the dental implant
industry. As BioLok has been experiencing growth which is well in
excess of the dental implant sector generally, we are very pleased to
have the entire BioLok team remain with the company to continue
executing on the growth strategy that has been impeccably implemented
for the past several years toward becoming a recognized and respected
global brand. Our mission is to continue unabated their passion for
excellence in the development and commercialization of high quality
dental products and servicing of dental practitioners."
It seems as if Healthpoint is trying to create a classic roll-up of sorts in
the dental implant industry and clearly they just might ignite a wave of more deals throughout the entire dental implant industry. The question of course is: Who will be the next acquisition candidate in the dental implant industry? But, of course, that’s for Wall Street to figure out. In the meantime, what are your thoughts on the recent deal activity in the dental implant industry? How will this change the current competitive landscape?
Biohorizon’s “unique selling proposition”, was their 4 thread options for different qualities of bone, but their new Prodigy implant, they settled on just one type of deap square threads on the implant. BioLock’s “unique selling proposition” is its laser grooves on the neck of the implant. This is supposedly to stop epithelial downgrowth, but there are no side-by-side studies to show any clinical advantage over any rough surface or over microthreads or grooves.
So the question is how to these two merged companies put there implant designs together so that they can have a uniform marketing story? Will we see laser grooves on the neck and deep square threads on the body? The trouble with merging two companies is coming up with a consistent story that does not offend the customers of either company who have bought into the marketing rhetoric of either company.